These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17405997)

  • 1. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
    J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
    Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
    J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
    Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.
    Vicini FA; Martinez A; Hanks G; Hanlon A; Miles B; Kernan K; Beyers D; Ragde H; Forman J; Fontanesi J; Kestin L; Kovacs G; Denis L; Slawin K; Scardino P
    Cancer; 2002 Nov; 95(10):2126-35. PubMed ID: 12412166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].
    Kawa G; Hiura Y; Satoh H; Sugi M; Fujita I; Oguchi N; Doi H; Ashida M; Okada H; Muguruma K; Murota T; Koyama Y; Kawamura H; Ohara T; Kawakita M; Matsuda T
    Hinyokika Kiyo; 2002 Mar; 48(3):133-8. PubMed ID: 11993205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
    Kuller LH; Thomas A; Grandits G; Neaton JD;
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):373-7. PubMed ID: 15006911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.